Status:

UNKNOWN

Targeted T-cell Therapy in Solid Tumors

Lead Sponsor:

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Collaborating Sponsors:

Shenzhen Second People's Hospital

Conditions:

Malignant Solid Tumor

Eligibility:

All Genders

18-75 years

Phase:

EARLY_PHASE1

Brief Summary

This is a single-center, open, single-arm controlled prospective clinical trial of patients with solid tumors treated with targeted activation of T cells through intravenous infusion.The purpose of th...

Detailed Description

In China, malignant tumors have become the leading cause of death for urban and rural residents, with solid tumors accounting for 77 percent.Immunotherapy is considered one of the most promising ways ...

Eligibility Criteria

Inclusion

  • Age: 18\~75 years old; 2. Patients with solid tumors still show progress after radiotherapy, chemotherapy and targeted therapy, with at least one measurable lesion; 3. No congenital autoimmune diseases or immunodeficiency diseases;' 4. At least one or more solid tumor targets of HER2, MUC1, CEA, EGFR and GPC3 were positive by immunohistochemical examination of tumor tissues; 5. No serious infectious diseases (hepatitis b, c, syphilis, AIDS); 6. Sign informed consent voluntarily. -

Exclusion

  • The researchers determined that the patient could not complete 6 courses of treatment.
  • 2\. Patients with t-cell lymphoma. 3. Pregnant or lactating female patients, or those who do not want to use contraception during the trial.
  • 4\. Allergic to both CT and MRI contrast agents and unable to conduct imaging evaluation.
  • 5\. Other patients in the treated group who were considered as unfit for cell therapy.
  • \-

Key Trial Info

Start Date :

May 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2021

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04076137

Start Date

May 1 2019

End Date

May 1 2021

Last Update

September 3 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of oncology, the second people's hospital of shenzhen

Shenzhen, Guangdong, China, 518055